Best Endometrial Cancer Doctors in Hyderabad - CION’s Dedicated Endometrial Cancer Panel

The best doctor for endometrial cancer is a gynae-oncologist (surgical oncologist with subspecialty training in gynaecologic oncology) for surgery, paired with a medical oncologist for adjuvant chemotherapy and immunotherapy when needed, and a radiation oncologist for vaginal brachytherapy or pelvic radiation. At CION, every endometrial cancer case is reviewed by a multidisciplinary tumour board, with surgical leadership by Dr. Paila Gowri Naidu (M.Ch Surgical Oncology, BHU Varanasi) — a female specialist with gynae-onc subspecialty training.

Around 95% of endometrial cancers present with post-menopausal bleeding — making this the clearest single warning sign in gynaecological cancer. Any vaginal bleeding after menopause is abnormal and warrants prompt evaluation, including pelvic ultrasound (to measure endometrial thickness) and endometrial biopsy. Most post-menopausal bleeding is not cancer, but evaluation is essential. Pre-menopausal women with very irregular bleeding, heavy bleeding, or bleeding between periods should also discuss endometrial assessment with their doctor. Early-stage endometrial cancer has excellent cure rates — but only if diagnosed early.

For most endometrial cancer patients — who tend to be post-menopausal — the standard treatment is total hysterectomy plus bilateral salpingo-oophorectomy (TH+BSO), removing the uterus, fallopian tubes, and ovaries. For a select group of younger women with very early disease (typically Stage IA Grade 1 endometrioid carcinoma, or atypical endometrial hyperplasia) who wish to preserve fertility, progestin-based fertility-sparing treatment is an option. This uses oral megestrol acetate (Megace) or a levonorgestrel-releasing intrauterine device (Mirena IUD) under close monitoring with repeat endometrial sampling every 3–6 months. Pregnancy should be pursued as soon as possible after complete remission. Definitive surgery (hysterectomy) is generally recommended after childbearing is complete. This pathway requires careful patient selection and is discussed at the first consultation for eligible patients.

Yes — testing for Lynch syndrome should be standard for every endometrial cancer. Around 5–10% of endometrial cancers occur in women with Lynch syndrome, an inherited condition that increases the risk of multiple cancers — particularly colon, ovarian, urinary tract, and small bowel cancers. Testing involves immunohistochemistry (IHC) for mismatch repair (MMR) proteins on the tumour, followed by microsatellite instability (MSI) testing and germline genetic testing if MMR deficiency is detected. If Lynch syndrome is confirmed, implications include: colonoscopy surveillance every 1–2 years starting age 25–30, increased surveillance for other Lynch-associated cancers, and genetic testing recommended for first-degree relatives (siblings, children, parents). Lynch-positive endometrial cancer also responds well to immunotherapy (pembrolizumab) for recurrent or advanced disease. CION’s tumour board ensures MMR/MSI testing on every endometrial cancer case and coordinates genetic counselling where indicated.

These are very different cancers despite being in nearby anatomical locations. Endometrial cancer arises in the lining of the uterus (the endometrium) and is most commonly adenocarcinoma; it typically affects post-menopausal women and is linked to obesity, diabetes, and unopposed estrogen exposure. Cervical cancer arises in the cervix (the lower part of the uterus) and is most commonly squamous cell carcinoma; it is HPV-related and typically affects younger women. Treatment differs substantially — endometrial cancer is surgery-first (TH+BSO), while locally advanced cervical cancer is treated with chemoradiation + brachytherapy. Family-screening implications also differ — Lynch syndrome for endometrial, HPV vaccination for cervical.

Modern endometrial cancer care uses molecular subtyping (developed from The Cancer Genome Atlas) to stratify cases beyond traditional stage and grade. The four subtypes are: POLE ultra-mutated (best prognosis — some patients may not need any adjuvant therapy), MMR-deficient / MSI-high (typically Lynch-associated; responds well to immunotherapy), p53-mutated / serous-like (worst prognosis; intensive treatment regardless of stage), and NSMP (no specific molecular profile; intermediate prognosis). This subtyping is increasingly used to personalise treatment recommendations. CION’s pathology pathway includes molecular subtyping where clinically indicated, in line with current NCCN/ESGO guidelines.

Yes — sentinel lymph node (SLN) mapping is the modern standard for surgical staging of endometrial cancer. Rather than removing all pelvic lymph nodes (full pelvic lymphadenectomy with significant lymphedema risk), SLN mapping uses indocyanine green (ICG) dye to identify and remove only the first-draining nodes for pathological assessment. This significantly reduces complication rates while providing accurate staging. CION’s gynae-onc surgical pathway uses SLN mapping where appropriate, particularly for early-stage disease.

It depends on the stage, grade, and molecular subtype. Stage I, Grade 1–2 disease with no high-risk features often needs no adjuvant treatment, especially for POLE-mutated cases. Stage I with high-risk features or Stage II often gets vaginal brachytherapy alone (a short, focused radiation course with few side effects). Stage III–IV typically requires combined chemotherapy (carboplatin + paclitaxel) and radiation. Recurrent or metastatic disease may receive pembrolizumab + lenvatinib (for MMR-proficient) or pembrolizumab alone or dostarlimab (for MMR-deficient). The full plan is determined at the multidisciplinary tumour board after final surgical pathology is complete.

A second opinion is especially valuable for endometrial cancer — both because adjuvant treatment decisions vary across centres based on stage and molecular features, and because fertility-sparing options may not be discussed at every centre. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your biopsy, imaging, and existing recommendation and provides a documented opinion you can take anywhere.

Costs vary by stage and treatment. Total hysterectomy + bilateral salpingo-oophorectomy with sentinel lymph node mapping ranges approximately ₹1,50,000 to ₹3,50,000; adjuvant chemotherapy (carboplatin + paclitaxel) ranges ₹1,50,000 to ₹3,00,000 over six cycles; vaginal brachytherapy ranges ₹50,000 to ₹1,50,000; pembrolizumab or dostarlimab immunotherapy is significantly higher per cycle. Fertility-sparing progestin therapy is much lower cost. For a detailed cost breakdown by treatment type, see our endometrial cancer treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate before treatment begins. Aarogyasri, EMI, and cashless insurance are accepted.